Biologic therapies and bone loss in rheumatoid arthritis
- 31 October 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 28 (2), 429-446
- https://doi.org/10.1007/s00198-016-3769-2
Abstract
Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive inflammatory polyarthritis. One of the most deleterious effects induced by the chronic inflammation of RA is bone loss. During the last 15 years, the better knowledge of the cytokine network involved in RA allowed the development of potent inhibitors of the inflammatory process classified as biological DMARDs. These new drugs are very effective in the inhibition of inflammation, but there are only few studies regarding their role in bone protection. The principal aim of this review was to show the evidence of the principal biologic therapies and bone loss in RA, focusing on their effects on bone mineral density, bone turnover markers, and fragility fractures.Keywords
Funding Information
- from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB
- Pfizer, Lilly, Merck, Sanofi, GSK, Amgen
This publication has 119 references indexed in Scilit:
- Inflammatory Rheumatic Disorders and BoneCurrent Rheumatology Reports, 2012
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI studyModern Rheumatology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends in Molecular Medicine, 2008
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis RegisterArthritis & Rheumatism, 2007
- Impaired skeletal development in interleukin‐6–transgenic mice: A model for the impact of chronic inflammation on the growing skeletal systemArthritis & Rheumatism, 2006
- Evolving concepts of rheumatoid arthritisNature, 2003